MEDIPOST announced that 3 year long term tracking clinical trial after ‘CARTISTEM^®’ injection was implemented, and the result proved safety with superior treatment effect vis-à-vis reference groups.

MEDIPOST implemented long term tracking clinical trial on the third phase clinical trial subjects for CARTISTEM^®’ injection and reference groups, at 10 clinical trial centers comprising Samsung Seoul Hospital etc.

MEDIPOST explained the result that ‘CARTISTEM^®’ was found as be far superior in treatment effect than reference groups in every assessment method comprising knee pain∙ function∙vitality assessment (IKDC), ostanthritis symptom assessment (WOMAC), pain index assessment (VAS) etc.

Firstly in IKDC assessment (increases in tandem with functionality), CARTISTEM^® treatment group’s average increase was higher by 3 times vis-à-vis the average increase by reference groups, by comparison of the status at pre-treatment and after 3 years from treatment. .

Also in WOMAC assessment (decreases in tandem with improving symptom) ‘CARTISTEM^®’ treatment group showed stronger improvement in ostarthritis, in with width of decrease which is more than 3 times vis-à-vis reference groups.

Also in the VAS assessment (decreases in tandem with lower pain) indicating the level of knee pain, ‘CARTISTEM^®’ treatment group obtained more than statistically meaningful scores than reference groups. .

Especially, ‘CARTISTEM^®’ treatment group and the reference group showed wider performance gap at the time of one year from the clinical trial than at the time of 3 phase test completion, in all assessment items, proving the superiority of ‘CARTISTEM^®’ in long term treatment effect such as sustained improvement of symptom and prevention of recurrence etc.